A personalized surveillance strategy according to risk stratification appears to be safe in the management of patients with serrated polyposis syndrome, reducing colonoscopy burden without risking an increased colorectal cancer incidence, a recent study has shown.
Use of tioguanine for at least 12 months appears to be effective in the maintenance treatment of inflammatory bowel disease (IBD), and while adverse events are common, most are clinically tolerable, according to a recent study.
Cognitive behavioural therapy (CBT), delivered over the web or phone, yields superior improvements in irritable bowel syndrome (IBS) symptoms and more favourable effects on life and mood in comparison with treatment as usual, according to data from the ACTIB* trial.
Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.
Hepatocellular carcinoma (HCC) patients receiving sorafenib may have poor survival if they present with pretreatment elevated platelets or have advanced Barcelona Clinic Liver Cancer (BCLC) stage, a recent study has shown.
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
The combination of metformin, nystatin, linagliptin, rivaroxaban and a high-protein diet is the main cause of nasoenteral tube obstruction, with corresponding odds ratios of 2.0, 3.1, 4.3, 2.4 and 1.9, according to a recent study.